Exciting News! Our Fundraising Partner Ritchies IGA, are launching their new Ritchies Card, incorporating the Community Benefit Program. . Every month, our organisation will receive 0.5%* of our members’ spend in Ritchies Stores PLUS our members will receive special offers and member only specials via the App. Featuring monthly promotions, cheaper prices for you, Collect […]
JDRF is excited to announce more than $2.7 million in funding to kick start five highly innovative research projects. The 2021 Pilot and Innovation Awards are designed to support innovative new directions for type 1 diabetes research, including concepts that have never been investigated before. The focus is on early-stage work that has a large […]
Our research roundups bring you the most exciting T1D research stories from around the world – the new advances in treatment, devices and knowledge that are making the biggest impact in the fight to cure, treat and prevent T1D. Here’s what you need to know in T1D research this month: New results from the ENDIA […]
Life-saving and life-changing technologies to measure blood glucose and deliver insulin in response to need are the foundation of type 1 diabetes (T1D) treatment and care in the 21st century. But in Australia, access to these technologies is inconsistent, inequitable, and incomplete. Even worse, they cut out for many on adulthood. This needs to change. […]
JDRF’s politician profiles are an opportunity to talk to people across the political spectrum and get an insight into their thoughts about type 1 diabetes, what their JDRF Advocate meetings mean to them and more. This month, we got in touch with Ross Vasta MP – Federal Member for Bonner and learned about the first […]
Every month, we’ll be putting a spotlight one of our incredible advocates who give voice to the lived experience of type 1 diabetes (T1D) and help politicians better understand the needs of the T1D community. Recently, we had a little chat with Dougal McGregor. Dougal is a 10-year old JDRF advocate from Shepparton, Victoria who has been […]
Mr Narev will bring more than 30 years of strategy and leadership experience garnered across consulting finance and technology businesses. JDRF Australia are delighted to welcome Ian Narev, Managing Director and Chief Executive Officer of SEEK to the Board. Mr Narev, who joined the Board at the September 2021 Board meeting, is no stranger to JDRF having spent several years as co-Chair of the JDRF Australia Advisory Board. Alongside his historical […]
Let’s meet the inspiring father-daughter duo who share a passion for BMX riding and a goal to help defeat type 1 diabetes. Daniel was diagnosed with type 1 diabetes (T1D) at a young age, but that didn’t stop him from becoming a proud father of two, a motorcycle racer, and a mentor and supporter to […]
Last year, JDRF appointed Dr Kirstine Bell from the Charles Perkins Centre, University of Sydney, to lead a pilot study to screen for risk of type 1 diabetes in the general population. Today, Dr Bell launched the national screening project and revealed new details about what it will involve. “Children are often diagnosed with type […]
UPDATED September 2022 Australia has rolled out two COVID-19 vaccines – one from Pfizer, and one from AstraZeneca. Both these vaccines are safe and effective at protecting people against COVID-19, and all Australians are encouraged to get vaccinated. With vaccines now being offered to people with T1D, we’ve gathered all the information you need to […]
JDRF Australia are delighted to welcome Professor Fabienne Mackay to the Board of JDRF Australia. Professor Mackay, who joined the Board at the June 2021 Board meeting, will also play an important role on JDRF’s Board Research Committee, evaluating and ensuring JDRF continues to support the best local research into type 1 diabetes (T1D). Prof. Mackay obtained her PhD from Louis Pasteur University in Strasbourg, France and has more than […]
JDRF and The Leona M. and Harry B. Helmsley Charitable Trust are excited to announce more than $1.2 million in new funding for three outstanding early-mid career Australian researchers. The ENDIA Early-Mid Career Science Accelerator Awards will support the researchers in carrying out new projects using samples collected as part of the ENDIA study, the […]
Our research roundups bring you the most exciting T1D research stories from around the world – the new advances in treatment, devices and knowledge that are making the biggest impact in the fight to cure, treat and prevent T1D. This month, the American Diabetes Association held their 81st Scientific Sessions. The world’s top type 1 […]
The past 12 months has been challenging in so many ways, particularly for our community. However, as with every challenge the resilient T1D community has been faced with, the pandemic, and the challenges it brought with it, has certainly not defined us. During this time, we’ve continued to see an almost limitless amount of courage, strength, and resilience from all of you. The challenges of the past 12 months and the impact COVID-19 has had […]
Today, we are excited to announce that two important members of the JDRF community have been appointed members of the Order of Australia as part of the Queen’s Birthday 2021 Honours List. Helen Maxwell-Wright We’re proud to be celebrating Helen Maxwell-Wright, Chair of our Victorian State Leadership Group and major supporter of type 1 diabetes […]
The Medtronic Minimed 770G will be added to the Federal Governments Insulin Pump Program – a significant step toward achieving our goal of more technology for more people through our policy agenda. So, what does this mean for you?
Australians living with type 1 diabetes (T1D) are disproportionately affected by a psychological phenomenon called decision fatigue, which hinders their ability to make vital decisions – placing them at greater risk of life-threatening complications such as heart attack and kidney disease.1 People living with T1D must make an extra 180 decisions every day compared to […]
A research breakthrough, funded by JDRF, has shown a promising future for the prevention of type 1 diabetes. Findings from a study by TrialNet show that the immunotherapy drug teplizumab can delay type 1 diabetes diagnosis a median of 2 years in children and adults at high risk. The study showed that teplizumab interferes with […]